News Release

International Wex and Sabex conclude agreement

Date: March 15, 2004

Toronto Stock Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. ("Wex") is pleased to announce the conclusion of a Manufacturing and Option Agreement with Sabex 2002 Inc. ("Sabex"). Under this agreement, Sabex will manufacture Wex's clinical lots for Canada, the United States and worldwide.

These negotiations, which were begun with Sabex Founder and Vice-Chairman of the Board, Michel Saucier, were concluded by President and CEO, Pierre Fréchette. The agreement provides Sabex with a first right of refusal to acquire an exclusive licence for Wex's injectable products in Canada.

Wex looks forward to this sharing of expertise as both companies implement their worldwide strategies and pursue accelerated expansion.

Sabex is a Canadian world-class corporation which develops, manufactures and distributes injectable and ophthalmic pharmaceutical products for the hospital and retail pharmacy markets in Canada, the US and other international markets.

Sabex's FDA approved manufacturing facilities produce injectable drugs in many critical specialty product categories, including narcotics analgesics, cardiovascular, psychotherapeutics, anti-infective and parenteral nutrition. More information about Sabex can be found at www.sabex.ca .

International Wex Technologies Inc., a publicly listed neuro-bioscience company (WXI), is focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, is a sodium channel blocker and is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

For additional information on our products visit us at http://www.wextech.ca or call Gordon Stanley, Corporate Communications at 604-683-8880, or at 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.